(NASDAQ: COLL) Collegium Pharmaceutical's forecast annual revenue growth rate of 3.09% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Collegium Pharmaceutical's revenue in 2026 is $815,186,000.On average, 10 Wall Street analysts forecast COLL's revenue for 2026 to be $26,403,855,510, with the lowest COLL revenue forecast at $25,158,041,762, and the highest COLL revenue forecast at $27,320,580,518. On average, 10 Wall Street analysts forecast COLL's revenue for 2027 to be $27,084,718,050, with the lowest COLL revenue forecast at $22,794,755,767, and the highest COLL revenue forecast at $29,431,534,070.
In 2028, COLL is forecast to generate $27,746,935,335 in revenue, with the lowest revenue forecast at $23,126,641,295 and the highest revenue forecast at $30,834,589,464.